ReviewTranslational gastroenterology and hepatology2018
Hepatocellular carcinoma in children: hepatic resection and liver transplantation.
Review in Translational gastroenterology and hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Sporadic Hepatocellular Carcinoma in an Adolescent Harboring a Somatic CDH1 Mutation: A Case Report and Literature Review.The Kaohsiung journal of medical sciences · 2026Article
- T1rho MRI as a quantitative biomarker of radiation-induced liver disease in normal and fibrotic rat models.Quantitative imaging in medicine and surgery · 2026Article
- Secular trend in universal hepatocellular carcinoma prevention: Taiwan, Poland, and Belgium experience.World journal of gastrointestinal oncology · 2025Article
- The Role of IR in Pediatric Liver Cancer.Seminars in interventional radiology · 2025Review
- Evaluation of surgical strategies and long-term outcomes in pediatric hepatocellular carcinoma.Pediatric surgery international · 2024Article
- Review on Pediatric Malignant Focal Liver Lesions with Imaging Evaluation: Part I.Diagnostics (Basel, Switzerland) · 2023Review
- Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.World journal of gastroenterology · 2022Article
- A case report of a teenager with hepatitis B surface antigen-positive multifocal hepatocellular carcinoma in a noncirrhotic liver.Clinical case reports · 2022Article
- The role of liver transplantation in the care of primary hepatic vascular tumours in children.Frontiers in oncology · 2022Review
- The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.International journal of molecular sciences · 2021Review
- Liver tumors in children with chronic liver diseases.World journal of gastrointestinal oncology · 2021Review
- Pediatric Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2020Review
- Rare malignant liver tumors in children.Pediatric radiology · 2019Review
- A Rare Case of Intracardiac Extension of Hepatocellular Carcinoma in a Child.Case reports in oncological medicine · 2019Article
- New trends and perspectives in hepatobiliary surgery: preface.Translational gastroenterology and hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a rare malignancy in children and at the time of diagnosis up to 80% of pediatric HCC are unresectable due to large and multiple lesions. The majority of pediatric HCC occurs on a background of normal liver, and consequently the absence of concomitant chronic liver disease generally allows tolerating pre- and post-operative chemotherapy. Based on the large experiences of adult HCC and pediatric hepatoblastoma, in the last years a multidisciplinary aggressive treatment composed of surgical resection and chemotherapy (based on cisplatin and doxorubicin) has been proposed, improving patient outcomes and recurrence rate in children with HCC. However, the overall survival rate in children with HCC is not satisfactory yet; while the 5-year survival rate may achieve up to 70-80% in non-metastatic resectable HCC, it remains <20% in children with unresectable HCC. The mainstay of the pediatric HCC therapeutic strategy is the radical tumor resection, weather by hepatic resection or liver transplantation, nevertheless the best surgical approaches as well as the optimal neoadjuvant and adjuvant treatment are still under debate. Different strategies have been explored to convert unresectable HCC into resectable tumors by extending criteria for surgical treatment and/or associating multi-modal treatments, such as systemic and local-regional therapy, but universal recommendation needs to be defined yet. The purpose of this review is to outline the role of different surgical approaches, including hepatic resection and liver transplantation, in pediatric HCC with or without underlying chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.